Hugel Inc (KQ:145020) — Market Cap & Net Worth
Market Cap & Net Worth: Hugel Inc (145020)
Hugel Inc (KQ:145020) has a market capitalization of $1.70 Billion (₩2.51 Trillion) as of August 1, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #6636 globally and #151 in its home market, demonstrating a -3.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hugel Inc's stock price ₩232500.00 by its total outstanding shares 10803292 (10.80 Million). See Hugel Inc capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hugel Inc Market Cap History: 2015 to 2026
Hugel Inc's market capitalization history from 2015 to 2026. Data shows growth from $484.67 Million to $1.70 Billion (14.34% CAGR).
Index Memberships
Hugel Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$202.56 Billion | 0.84% | #19 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$202.56 Billion | 0.84% | #19 of 1384 |
Weight: Hugel Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hugel Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hugel Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Hugel Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Hugel Inc's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $783.62 Million | $124.19 Billion | $43.27 Billion | 0.01x | 0.02x |
| 2017 | $1.37 Billion | $182.09 Billion | $72.83 Billion | 0.01x | 0.02x |
| 2018 | $931.02 Million | $182.39 Billion | $69.74 Billion | 0.01x | 0.01x |
| 2019 | $970.55 Million | $204.57 Billion | $44.61 Billion | 0.00x | 0.02x |
| 2020 | $1.37 Billion | $211.04 Billion | $41.99 Billion | 0.01x | 0.03x |
| 2021 | $1.12 Billion | $245.15 Billion | $57.73 Billion | 0.00x | 0.02x |
| 2022 | $987.63 Million | $281.68 Billion | $57.33 Billion | 0.00x | 0.02x |
| 2023 | $1.09 Billion | $319.70 Billion | $93.08 Billion | 0.00x | 0.01x |
| 2024 | $2.05 Billion | $373.05 Billion | $135.81 Billion | 0.01x | 0.02x |
| 2025 | $1.69 Billion | $425.11 Billion | $140.87 Billion | 0.00x | 0.01x |
Competitor Companies of 145020 by Market Capitalization
Companies near Hugel Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Hugel Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Hugel Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Hugel Inc's market cap moved from $484.67 Million to $ 1.70 Billion, with a yearly change of 14.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.70 Billion | +0.87% |
| 2025 | ₩1.69 Billion | -17.83% |
| 2024 | ₩2.05 Billion | +87.75% |
| 2023 | ₩1.09 Billion | +10.75% |
| 2022 | ₩987.63 Million | -12.12% |
| 2021 | ₩1.12 Billion | -18.26% |
| 2020 | ₩1.37 Billion | +41.66% |
| 2019 | ₩970.55 Million | +4.25% |
| 2018 | ₩931.02 Million | -31.83% |
| 2017 | ₩1.37 Billion | +74.28% |
| 2016 | ₩783.62 Million | +61.68% |
| 2015 | ₩484.67 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Hugel Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.70 Billion USD |
| MoneyControl | $1.70 Billion USD |
| MarketWatch | $1.70 Billion USD |
| marketcap.company | $1.70 Billion USD |
| Reuters | $1.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more